Mayo Biopsy Marker

Overview

About this study

This is a Phase 0 clinical trial to evaluate a twinkling biopsy marker (Patent Application Title: Non-Metallic Ultrasound-Detectable Markers Patent Application No.: 62/903,078, Application Type:  Provisional) for ultrasound conspicuity in patients with breast cancer and locally advanced disease involving the axillary lymph nodes.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

 

  • Patient 18 years or older with breast cancer and biopsy-proven malignant involvement of an axillary lymph node
  • Patient is not pregnant.
  • Surgical management involves preoperative radioactive seed localization of the positive axillary lymph node
  • Surgery will be performed by Dr. James Jakub, Department of Surgery, Mayo Clinic, Rochester, MN
  • Radioactive seed localization is scheduled in the afternoon with surgery anticipated next day or later 
  • Patients must be able to understand the study procedures and comply with them for the entire length of the study.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Christine Lee, M.D., Ph.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Christine Lee

(507) 266-1207

lee.christine@mayo.edu

More information

Publications

Publications are currently not available